Replies to post #243076 on Amarin Corp Plc (AMRN)

[irishpaddy]

Of course capitalism needs a heart that's why we risked our money into developing this amazing product. If Reduce it failed we took the loss. Yes a volume product by all means but it's JT's job to maximise our financial return. We have cared enough about the patient by funding this life saving drug, now charge to the maximum limit of safe returns.

[rosemountbomber]

"IMO this strategy will kick in as soon as Amarin can post positive earnings"

Zip are you saying that after earnings are positive, JT will lower the price?

[MateoPaisa]

Im calling BS. The company has a duty to maximize profit. If you want to donate your money ro those who can’t afford it, then go for it, but don’t think the BBs give a rats arse who can or can’t afford it. They want money, not warm feelings

[TastyTheElf]

ziploc I'm not going to bash you but I do want to note that other companies with inferior medicines for the same general indication charge an ABSOLUTE FORTUNE for their garbage and make no apologies.

Captalism should have a heart, but a company with an innovation of this magnitude, and investors to reward for their steadfast risk-taking, has to balance affordability with return on investment. Otherwise innovation dies the old-fashioned way -- meaning, the European way.

You've read the ICER reports and other measures of cost/benefit, I'm sure. It's a rare drug that has the cost/benefit profile of Vascepa. It rocks the status quo, and all the Big Pharma competitors hate it, and the cockroaches will do anything to stop its progress, and to accuse AMRN of profiteering on Vascepa is incredibly unfair.

Vascepa is priced for the masses already. If insurance carriers decide to arbitrarily create barriers to affordability while kissing the asses of their bigger Pharma partners, that isn't AMRN's fault. Over time, the efficacy of the drug will steamroll all the political bullshit.

AMRN isn't required to be the bagholder for redressing Big Pharma greed. AMRN/Vascepa is the pattern buster when it comes to Big Pharma soaking the poor for small incremental health benefits.

[Whalatane]

Zip. Amarin could double the price of Vascepa for R-It profile patients and their insurers would still save money ... ICER report

For those who aren’t in or close to the R-It profile .... why should they have low cost access to Vascepa ?

Kiwi